Search
News & Events
WA health experts say junk food and sugary drink sponsorships have no place in sportWA’s peak public health and medical experts have united in their call to end the sponsorship of sport by junk food companies.
News & Events
Slime, bugs and bacteria: Hands-on science fun at the Telethon Family FestivalKids and families can get their hands dirty at Sunday’s Telethon Family Festival at RAC Arena, with The Kids Research Institute Australia showcasing some of its world-class research.
News & Events
Major conference tackles FASD from the head and the heartHundreds of delegates from around Australia, Canada and New Zealand arrive in Perth this week to discuss the latest knowledge about fetal alcohol spectrum disorder (FASD) at the 2nd Australasian FASD Conference 2018.
News & Events
‘Nicotine-free’ e-juice samples found to contain nicotine and harmful chemicalsSix out of ten ‘nicotine-free’ e-cigarette liquids analysed by The Kids Research Institute Australia researchers contained nicotine as well as an acutely toxic chemical typically found in pesticides and disinfectants.
News & Events
New study uncovers dual benefit of bone-protecting treatment for childhood leukaemiaA groundbreaking study from cancer researchers at The Kids Research Institute Australia has identified a promising new therapeutic strategy for children battling the most common childhood cancer – B-cell acute lymphoblastic leukaemia.
News & Events
Meningococcal research paves way for vaccine useA series of The Kids Research Institute Australia studies looking at safety for Meningococcal ACWY vaccines in children has led the way for its use in Australia.
Research
A Phase III, randomized, controlled, observer-blind study to demonstrate effectiveness, immunogenicity and safety of GSK's meningococcal Group B and combined ABCWY vaccines when administered to healthy adolescents and young adults (Quintet)Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical
Research
A randomized, controlled, observer-blind, phase 1/2a study to evaluate the safety, reactogenicity, and immunogenicity of Ad26.RSV.preF in RSV-seronegative toddlers 12 to 24 months of ageJennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical
Research
Pertaprime: An investigator-driven phase II-III randomised, observer-blind, controlled trial to demonstrate non-inferior immunogenicity of Pertagen® in comparison to Boostrix® in healthy young Australian adults aged 18-25 yearsJennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical
News & Events
$1.2million in funding secured for two innovative projectsThe Kids researchers are collaborating on two major projects that today received $1.2million in funding from MTPConnect.